Marker Therapeutics Inc (MRKR)

[Inoviorulez]

If the PC data comes out solid not only would it increase the share price, but it would bring big pharma swarming for a partnership deal. I think you are right in that Marker wouldn't settle for a lowball offer. That's because pancreatic cancer has been the toughest nut to crack.

I read recently this article where Celgene combined its drug Abraxane with gemcitabine for pancreatic cancer and it failed for late-stage pancreatic cancer patients. There was some improvement in overall survival though nominally over gemcitabine alone.

https://www.biospace.com/article/celgene-s-abraxane-fails-to-hit-the-mark-in-a-phase-iii-pancreatic-cancer-study/